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Abstract
Purpose The purpose of this review is to provide guidance
that aids in the practical design, implementation, and analysis
of medication use evaluations (MUEs) for postsurgical pain
management.
Summary Clinicians have long employed drug use evalua-
tions or drug utilization reviews to ensure the safe and appro-
priate use of medications in a hospital, medical practice, or
other healthcare setting. Although these approaches are valu-
able, there is a growing trend toward replacing these methods
with the MUE, a performance improvement tool that focuses
on assessing and improving medication use processes or med-
ication treatment response with the goal of optimizing patient
outcomes. Utilizing MUEs to assess patient outcomes and
quality of life can be challenging in certain therapeutic areas
such as pain management, where measurements of pain can be
quantitative but are inherently subjective. Currently, there is
little guidance on the development of MUEs that balance sub-
jective and objective outcomes.
Conclusion MUEs continue to become the standard for qual-
ity improvement for optimizing care and ensuring optimal
outcomes. This review of the literature provides guidance in
post-surgical pain management, an area that requires measure-
ment of both subjective and objective outcomes.
Keywords Drug use evaluation .Medication use evaluation .
Postsurgical pain . Surgery
Introduction
As the number of options for managing postsurgical pain con-
tinues to expand, healthcare providers and administrators have
a growing need for a systematic method of evaluating and
selecting which drugs or delivery systems are most likely to
help their patients. Clinicians have long turned to drug use
evaluations (DUEs) or drug utilization reviews (DURs) to en-
sure the safe and appropriate use of medications (e.g., dose and
duration of treatment or avoiding drug/drug interactions), but
those methods typically do not provide sufficient data to make
an informed decision on whether drug A is better than drug B
for managing pain in a specific postsurgical patient population.
To address those types of questions, the traditional DUE/
DUR has been expanded into a medication use evaluation
(MUE), a performance improvement tool that focuses on assess-
ment and improvement of medication use processes or medica-
tion treatment response with the goal of optimizing patient out-
comes [1, 2]. A comprehensive review of MUEs published in
2014 by Fanikos and colleagues recommended using MUEs in
three following situations: when the benefit of the medication is
unknown, when there are little data available to influence a
choice between two medications, and when there is a need to
analyze the process of medication prescribing, preparation, dis-
pensing, administration, andmonitoring [2]. MUEs, which have
many parallels to investigator-initiated clinical trials, can be used
to investigate individual drugs, therapeutic classes, disease
states, or medication use processes [1]. In postsurgical pain,
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MUEs typically compare specific drugs, classes of drugs (e.g.,
opioids), or methods of drug delivery (e.g., local, oral, IV) [2].
A key aspect of MUEs is their emphasis on patient out-
comes and quality of life [1–3]. This defining feature also
provides the greatest challenge, as these types of endpoints
often can be difficult to assess quantitatively and/or objective-
ly [2]. The choice of endpoints can be particularly complex in
pain management, as measurements of pain can be quantita-
tive but are inherently subjective. It is possible to use more
objective outcomes, such as functional improvement or length
of hospital stay, but the relationship of those outcomes to
postsurgical pain management frequently is unclear.
These challenges aside, the authors believe the value of
MUEs in postsurgical pain management outweighs any poten-
tial hurdles and involved in creating a scientifically robust
research protocol with carefully chosen endpoints. The pur-
pose of this manuscript is to provide an educational resource
to aid in the practical design, implementation, and analysis of
MUEs for postsurgical pain. For ease of discussion, we have
separated the process into five following sections: establishing
responsibility, developing scope and objectives, designing the
MUE, finalizing the protocol and analyzing data, and
interpreting the results and making recommendations.
Establishing Responsibility
Even MUEs that are meticulously designed and flawlessly
executed are likely to be unsuccessful without engagement
and support at several levels of the institution [2]. Most insti-
tutions’ task existing committees (e.g., Pharmacy and
Therapeutics, Drug and Therapeutics, Quality Management)
with overseeing the MUE process, including choosing the
topics to be evaluated, establishing the policies and proce-
dures to be followed, and implementing any necessary chang-
es to prescribing or clinical practice based on the findings [1,
3].
Specific MUEs are typically managed by a collaborative,
interdisciplinary team that includes a pharmacist, prescriber,
nurse, administrator, and a representative of any other
healthcare profession relevant to the MUE (e.g., lab techni-
cian, physical therapist, nutritionist) [1, 2]. For postsurgical
pain, an MUE committee might consist of a pharmacist, a
surgeon, an anesthesiologist, a nurse in the postanesthesia care
unit, a floor nurse, and a physical therapist. MUEs are com-
monly spearheaded by pharmacists, but the roles of all team
members may vary based on the goals and objectives of the
MUE, the practice setting, and the available resources [1].
Developing Scope and Objectives
Historically, the most common driver for the development and
implementation of DURs, DUEs, and MUEs has been cost.
However, the key benefit of MUEs is that they also can be
effectively employed to address a wide range of issues related
to patient-specific outcomes, such as safety, medication effec-
tiveness, appropriate dosing, and quality standards [1–3]. Start
the MUE process by clearly identifying the medical need or
question in as much detail as possible [3]. For example, the
statement, “We need to find out why we are using so much of
drug A,” is insufficiently descriptive. Add specificity by con-
sidering questions such as: “Which medical specialty is pre-
scribing drug A the most?”, “Has there been a sudden increase
in use of drug A?”, “Is there concern about a specific adverse
event with drug A?”, and “Are insurance companies refusing
to cover drug A?” Depending on the answers, a more suitable
statement of medical need might be, “In the last year, use of
drug A increased 27% in the intensive care unit (ICU).
However, drug A has been associated with higher rates of rash
in acutely ill patients. “Is drug A being used appropriately in
this setting?”
The next step is to translate the medical need into one or
more specific, measureable objectives. Using the example
above, consider how to define appropriate use. Is the concern
over any use of drug A in the ICU incorrect dosing, use of
drug A in combination with drug B costly, or some other
issue? Depending on the responses, potential MUE objectives
might be the following: [1] establish whether the increase in
use is the result of a greater number of patients requiring drug
A, or higher doses of drug A being prescribed, [2] determine
the percentage of ICU patients using drug Awho have subse-
quent new prescriptions for antihistamines or oral steroids to
treat rash, and [3] compare the ICU length of stay between
patients not exposed to drug A, patients exposed to drug A
who did not develop a rash requiring additional medications,
and patients exposed drug A who had subsequent new pre-
scriptions for antihistamines or oral steroids.
Some institutions routinely forgo the systematic generation
of MUE objectives, often because they feel the answers are
obvious. However, these early decisions are critical to the
design of the MUE, and devoting resources to developing a
robust scope and measurable objectives is likely to save time
and resources later in the MUE process.
Designing the Study
Though rarely as complex as a clinical trial, a well-designed
MUE should follow a prespecified protocol that includes
many of the same following elements: study design, popula-
tion, endpoints, data collection, and statistical analyses.
Study DesignMUEs are typically performed at a single cen-
ter, but they can be prospective (when the prescription is
filled), concurrent (during treatment), or retrospective (after
an endpoint has been reached or treatment is completed) [4].
When evaluating postsurgical pain management, MUEs are
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typically retrospective and compare two or more drugs/drug
classes, delivery methods, or surgical techniques. The struc-
ture of the comparison (e.g., intervention vs. standard of care,
matched case-control) depends on the objectives of the MUE
and the available data. For example, an MUE by Kampe et al.
compared outcomes from patients undergoing thoracotomy
who were given one of two drugs, whereas a different MUE
from Kelly and colleagues used a case-control design to eval-
uate the use of intravenous (IV) acetaminophen in knee
arthroplasty [5, 6].
Population When determining the population to be studied,
many variables need to be considered, including sample size,
time period for data collection, and inclusion/exclusion
criteria. In most cases, the sample size and time period for
data collection are based on practical rather than statistical
considerations. There are no firm rules, but MUEs often in-
clude a few dozen to a few hundred patients who are treated
within a 1- to 3-year period [5–8]. Larger sample sizes are
generally desirable, but there is almost always a need to bal-
ance rigor and practicality. On one hand, extending the time
period to include additional patients might introduce bias if
any changes were made to the standard of care from the be-
ginning to the end of data collection, but on the other hand, a
change to the standard of care may present an opportunity for
evaluation. For example, Kaplan et al. examined two follow-
ing groups of patients undergoing total knee arthroplasty: a
control cohort treated with standard of care between July 1,
2012, and December 31, 2012, and an intervention group
treated with a new drug formulation between July 1, 2013
and January 31, 2014 [8].
Well-considered inclusion/exclusion criteria can strengthen
an MUE by helping to eliminate bias introduced by
interpatient heterogeneity. In postsurgical pain management,
individual MUEs should be restricted to a single surgical in-
tervention (e.g., total knee arthroplasty, thoracotomy, Roux-
en-Y-gastric bypass) and, with the exception of the variable(s)
under study, with as little variation as possible between sur-
geons, surgical procedures, and drug delivery techniques.
Exclusion criteria can also be used to protect patient safety
(e.g., by excluding patients with known hypersensitivity to
opioids, bupivacaine, etc.) and preserve the integrity of the
data (e.g., by excluding chronic opioid users or patients with
incomplete documentation) [5–8].
Endpoints The choice of endpoints is based on the objectives
of the MUE. Ideal endpoints are objective (vs. subjective),
measurable (either qualitative or quantitative), relevant, and
use data that is reasonably easy to obtain [2]. When designing
an MUE, it may be helpful to distinguish between variables
(e.g., opioid dose, pain score) and the application of those
variables to yield endpoints (e.g., difference in opioid dose,
change in pain score) [2]. Table 1 [5–8] lists variables that are
commonly used in MUEs for postsurgical pain, detailing the
pros and cons of each and providing examples of potential
endpoints.
The table also includes a list of questions that may help
define the endpoint more precisely and improve the quality
and specificity of the data. One of the most critical questions
to ask is, what is the clinical relevance of an endpoint? For
instance, what is a meaningful difference in pain score or
length of hospital stay in terms of patient outcomes? Would
an endpoint of no overall change in pain score be clinically
acceptable if it were accompanied by a significant increase in
one or more functional measures? Unfortunately, there are too
many potential confounders to suggest any firm rules, so de-
cisions about what constitutes a meaningful difference should
be made during the MUE design phase using the clinical
knowledge and experience of the MUE team members [4].
Choosing endpoints in postsurgical pain management can
be particularly challenging because of the inherently subjec-
tive nature of pain and the frequent interaction between the
endpoints. For example, what does it mean if drug A improves
a functional outcome (e.g., range of motion) without signifi-
cantly lowering mean pain score in comparison with drug B?
Does that result imply that drug A is unable to effectively
lessen pain, or does it suggest that patients taking drug A
can tolerate higher levels of activity without increasing pain
than patients taking drug B? The MUE design phase is an
ideal time to consider these types questions and, if possible,
identify somemethod of extracting that information during the
study.
Data Collection Plan This part of the MUE study design
should detail who, what, where, when, and how the data will
be collected. Examples for each category are provided in
Table 2 [2, 5–8]. Some endpoints, such as pain scores or
satisfaction ratings, may require data from the patients them-
selves. Fanikos and colleagues encourage MUE designers to
prospectively consider whether the collection procedures have
the potential to significantly disrupt or negatively impact pa-
tient care, and to adjust the study design accordingly [2].
Statistical AnalysisOne of the biggest challenges faced when
designing an MUE is the ability to identify and resolve the
numerous statistical subtleties that can significantly impact
outcomes. Just like any clinical study, the identification of
appropriate endpoints, establishing clinically relevant con-
trols, and establishing the appropriate statistical test for study
objectives are keys when developing the statistical plan for an
MUE. There are several statistical questions that the investi-
gators should consider as a part of the statistical plan (Table 3)
[5–8]. When possible, consultation with an experienced stat-
istician may be helpful in ensuring a robust design.
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Table 1 Potential endpoints for medication use evaluations in postsurgical pain [5–8]
Variable Pros Cons Potential endpoints Clarifying questions
Opioid use • Objective• Easy to
measure with
prescription records
• Usage may vary widely between
patients for subjective reasons
(difference in pain threshold, AEs,
tolerance)
• Change in opioid use
over time via pill
counts
• Difference in total
opioid use between
treatment groups
• Reduction in total
morphine equivalents
• Percentage of patients
discharged on opioids
• Constipation rates
• Are the opioids self-administered,
dispensed on request, or administered
when a predetermined threshold pain
score is reached?
• When does the measurement period
begin/end?
• What is a clinically meaningful
difference?
Pain scores • Easy to administer•




• Subjective• Likely to vary widely
between patients
• Absolute change in pain
intensity or pain relief
over time
• Percentage change in
pain intensity/relief
over time
•Difference in pain scores
between treatment
groups
• 30 and 50% responder
analysis
• Average pain score at
discharge
• When does the measurement period
begin/end?
•What is the interval for data collection and
the allowable variation (e.g., 6 ± 1 h,
24 ± 4 h)?
• Are data collected when the patient is at
rest or during activity (e.g., coughing
after thoracotomy)?






• Focused on patient
outcomes
• May be measured as
part of standard care
• Changes may or may not be driven by
pain
• Change in range of
motion over time
• Time to ambulation
• Percentage of physical
therapy sessions
completed
• Time to return to
work/normal activities
after surgery
• What changes in functional measures are
appropriate to measure for a patient 24 h
postsurgery?
• Are the outcome and the use of pain
medications temporally related (e.g.,
patients may taper off opioids long
before they return to work)?
• When are data collected?




• May be objective
• May be captured as
part of normal care,
particularly if
serious
• May be subjective
•May or may not be associated with use
of pain medication (e.g., constipation,
infection)
• Incidence in each
treatment group
• Time to resolution
• Percentage of patients
with serious AEs in
each treatment group
• Which AEs are of interest?
• When does the measurement period
begin/end?








• May be affected by non–pain-related
factors (e.g., comorbidities that slow
healing, clinicians’ schedules, patient
transportation)
• Difference of total
length of stay between
treatment groups
• Differences in level of
care (e.g., intensive
care stay)




threshold (e.g., 3 days)
• When does the measurement period
begin/end?
• Does the precision of the endpoint match
the precision of the data (e.g., reporting
the mean length of stay in minutes when
the data are routinely rounded to the
nearest hour)?
• What is a clinically meaningful
difference?




• Not a patient-oriented endpoint, which
is the primary goal of an MUE (cost
can be a component of an MUE but
should not be the focus)
• Difference between
treatment groups
• Does the cost include the drug only? Are
there relevant differences in equipment,
personnel time, etc., between treatments
that should be included?
• What is the cost basis (e.g., what
institution bills vs. what insurance
company or patients pay)?
• What is a meaningful difference?
• What is an appropriate tradeoff between
cost and outcomes?
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Finalizing the Protocol and Analyzing Data MUEs almost
always involve protected health information, so once the de-
sign is complete, the next step is to obtain approval from an
institutional review board. Training on the protocol should be
provided to relevant staff, and periodic quality checks are
highly recommended throughout the data collection period
[2]. Once the database is complete, proceed through the sta-
tistical analysis exactly as planned. It is inappropriate to add or
modify endpoints after the data are collected, unless the results
are clearly labeled as a post-hoc analysis and interpreted with
caution.
Interpreting Results and Making Recommendations
When the data have been analyzed, the MUE team should
meet and discuss the interpretation of the results from both a
statistical and a clinical perspective. It may be worthwhile to
reexamine some of the questions and issues considered during
the design phase. Did the MUE meet its objectives? Was the
appropriate patient population included? Were there any
known shifts in the standard of care during the data collection
period? How confident is the team in the quality and accuracy
of the data? Do the results show a clinically relevant difference
between drugs? What are the possible explanations for the
Table 1 (continued)




• Focused on patient
• Likely to encompass
efficacy and safety
• Subjective
•May be difficult to separate satisfaction






• Is the endpoint general patient satisfaction
with medical care, or should it be more
focused on pain management?
• What is the measurement period or
interval?
• What is a clinically meaningful
difference?
AEs adverse events
b Choice depends on type of surgery; examples include pulmonary function, time to resume work/normal activities, physical therapy goals, range of
motion, etc.
Table 2 Examples of data collection procedures [2, 5–8]
Who • MUE team members
• Additional point-of-care providers
• Other designees (e.g., medical students
and interns) with proper training
and supervision
What • Demographics (e.g., age, gender, weight)
• Designated primary endpoint(s)—
subjective/objective
• Secondary endpoint(s) —subjective/objective
• Potentially confounding factors
(e.g., comorbidities, simultaneous
surgeries, opioid tolerance)
Where • At point of care
• Retrospectively extracted from a database
(e.g., medical or prescription records,
insurance claims)
When • Prespecified time period (e.g., from
January 2014 to December 2014)
• At what interval (e.g., every 6 h, once per wk)
How • Collated on paper or in a spreadsheet
created by the person collecting the data
• Using paper or electronic data collection
forms created by the MUE team
• Using validated surveys or scores
(e.g., pain, patient satisfaction)
• Reports and queries from databases
MUE medication utilization evaluation
Table 3 Key statistical questions to address when designing a
medication use evaluation [5–8]
Design • Does the study have appropriate controls or
comparator groups?
• Are all the needed analyses specified in the
study design?




•Will the data be checked for normal distribution
before applying descriptive statistics (e.g.,
mean, standard deviation, median)?
• What are the criteria for including or excluding
outliers?
• What is the appropriate comparison test for the




• If needed, what is the appropriate statistical
model for the anticipated data (e.g., linear
regression, logistic regression, analysis of
variance)?
• How will the model be adjusted for potentially
confounding factors (e.g., unequal baseline
characteristics, multiple surgeons, different




• What is the threshold for significance? An
explanation may be required if anything
besides p < 0.05 is chosen.
• How will results that are statistically significant
but not clinically different be interpreted?
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outcomes? When possible, maintain the spirit of an MUE by
prioritizing the results of patient-focused endpoints [2]. Also
reconsider the tradeoffs between the medications under study.
For example, is it worthwhile to spend more on a drug A if
does not reduce mean pain scores but does significantly im-
prove functional status (e.g., range of motion) compared with
drug B?
The end product of the discussion should be a consensus as
to how the MUE results should be applied. Is a change in
prescribing or standard of care warranted? If yes, who needs
to be notified? What is the appropriate time period for imple-
mentation of the change? What is the best way to communi-
cate the information? Is there a need for a follow-up MUE to
assess compliance to the change or success of its implemen-
tation? This meeting is also an ideal time to assess the MUE
process itself and plan for any needed improvements [3, 4].
Since literature in this area is scant, also consider publishing a
detailed account of the MUE design, outcomes, and data
interpretation.
Case Example: Postsurgical Pain Management
Medication Use Evaluations To elucidate some of the intri-
cacies related to the development of an MUE in the area of
postsurgical pain management, we present the following case.
A clinical pharmacist with responsibilities in the surgical
unit has received several requests from her anesthesiologist
and surgical colleagues regarding the use of a newly approved
medication for the management of surgical pain. The new
medication (referred to for the purposes of this example as
doloremol) has provisional status from the Pharmacy and
Therapeutics committee (P&T) and requires adherence to a
strict protocol for its use. Doloremol is a non-opioid,
centrally-acting analgesic that can be delivered intravenously
during surgery, and there is recently published data supporting
its use in orthopedic surgery. While many of the surgeons at
this institution have found doloremol to be beneficial for their
patients, there are no published studies on the medication’s
effect on outcome measures, such as reduction of opioid use
or impact on length of stay. The clinical pharmacist deter-
mines that a MUE should be conducted to determine if use
of doloremol should become a permanent part of the postsur-
gical management pain management protocol for her unit.
Establishing Responsibility Because the surgery and anes-
thesiology departments were already interested in providing
doloremol for patients, the clinical pharmacist identified indi-
viduals in these departments with whom to collaborate for the
development of the MUE protocol and obtained preliminary
authorizations from these departments.
Developing Scope and Objectives Prior to determining any
elements of theMUEwith her assembled team, the pharmacist
evaluated the literature for additional information on
doloremol that might inform MUE development or serve as
background information on the unmet need for a treatment
like doloremol. The pharmacist searched the following data-
bases: PubMed (http://www.ncbi.nlm.nih.gov/pubmed), the
Cochrane Database of Systematic Reviews (http://www.
cochranelibrary.com/cochrane-database-of-systematic-
reviews/index.html), the National Health Service Economic
Evaluation Database and Database of Abstracts of Reviews
of Effects (http://www.crd.york.ac.uk/crdweb/), and the
Central Register of Controlled Trials (http://www.
cochranelibrary.com/about/central-landing-page.html). Her
search identified additional doloremol dosing approaches
that were used by several other institutions to manage
several surgical conditions. One of these dosing regimens
was added to the MUE analysis as a comparator to the
dosing regimen currently in place in the surgical unit.
The MUE developers determined that the objective of this
study would be to evaluate the effect of IV doloremol on pain,
opioid use, and hospital length of stay when used in orthopedic
surgery. The hypothesis was that, when administered during hip
replacement surgery, IV doloremol (administered via either
dosing arm) compared to a historical control would reduce
the morphine equivalent dose of postsurgical opioids, with no
difference in pain scores, reduced length of stay, and/or in-
creased physical therapy time within the first 48 h after surgery.
Designing the Study While approaches to designing MUEs
vary from institution to institution, the MUE described in this
scenario required a series of forms to be completed, to outline
goals and objectives, the need for the study, inclusion and
exclusion criteria, study procedures, statistical analyses, antic-
ipated safety risks to the patients, and procedures for ensuring
confidentiality. In addition to completing forms pertaining to
study details, the team also needed to fill out forms for data
gathering, consent, and storage and distribution of the medi-
cation. Many of these forms were standardized by the institu-
tion for use with research activities and may be available at
other facilities. It is important to obtain these forms early in the
process to facilitate MUE protocol development. If a team is
developing new forms, such as those for data collection, it is
important to trial these forms for a few test patients prior to
finalizing, which will allow the team to identify potential bar-
riers and provide solutions prior to implementation.
In order to assess the primary endpoint, reduced morphine
equivalent dose of postsurgical opioids at 48 h postsurgery,
the clinical pharmacist had to develop an assessment proce-
dure to ensure that each patient’s pain and opioid use were
assessed immediately with postsurgery 48 h later. In this case,
the clinical pharmacist had access to patients’ opioid medica-
tion doses and administration timing through the electronic
medical record (EMR). The secondary endpoints, including
difference in pain scores, reduced length of stay, reduced
costs, and/or increased physical therapy time also would be
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readily available through the EMR. All adverse reactions and
toxicities would be recorded in the subject’s EMR as well.
The pharmacist and her colleagues established that differ-
ences in means would be considered significant for p < 0.05.
A one-tailed t test was selected to show decreased opioid use
with IV doloremol, and two-tailed t tests were intended to
show no difference with respect to mean change in absolute
pain score and mean cost endpoints.
It was determined that 50 prospective patients would be
necessary for each dosing arm to conduct the statistical anal-
yses. Additionally, there would be a need to evaluate 200
historical controls, which would include patients treated in
the surgical unit over a 4-year period.
Finalizing the Protocol and Analyzing Data The proposal
forms were completed by the clinical pharmacist and were
given to the rest of the MUE team for review prior to submis-
sion. Depending on the institution, proposals usually will need
to be submitted to the institutional review board (IRB) and
potentially other internal peer-review committees to allow
for objective oversight to ensure patient’s safety. Since the
pharmacist’s institution is an academic one, theMUE proposal
also was submitted to the university IRB. In some cases, these
submissions can be done in parallel.
The P&T committee and the IRB group reviewed the sur-
gical unit protocol and provided direction to refine several
aspects of the proposal. Once refined and approved, the
MUE team took 2 weeks to educate the various departments
that would be exposed to the study protocols, including phar-
macy, surgery, anesthesiology, nursing, physical therapy, and
administration.
Interpreting the Results and Making Recommendations
The study was conducted over a 6-month period and evaluat-
ed 100 patients undergoing hip replacement surgery using
either of the two dosing regimens of doloremol, along with
review of data from 200 historic controls. The data collected
from the MUE was then compiled and analyzed by the MUE
working group. A summary of the data was presented to the
P&T committee so its members could assess the potential
benefit of changing the surgical unit protocol for perisurgical
pain management. In other facilities, this data should be
shared with all of the departments taking part in the MUE,
because elements of the data may lead to improvements in
processes within other departments or serve as learnings for
future MUEs.
In addition to sharing the data with internal stakeholders, it
is important to present the data externally. Surgical, anesthe-
siology, and pharmacy congresses would all be interested in
learning about the development and value of an MUE like the
one described in this case. It is important to involve authors
who helped to develop the MUE protocol and are relevant to
these audiences (e.g., having a surgeon on the MUE team
serve as lead author for a surgical congress). Additionally, it
is important to publish this information in a peer-reviewed
publication. Journal article authorship should be reserved for
individuals who were involved with the design and execution
of the MUE.
Future Directions At present, MUEs typically are performed
at a single institution or within an integrated healthcare sys-
tem. The next step in the evolution of MUEs is the develop-
ment of multicenter protocols, which, in transcending the cur-
rent practice of extracting data from claims databases or elec-
tronic medical records from a single site, would increase sam-
ple sizes and allow for evaluation that takes into account var-
iations in geographical location, type or size of institution, etc.
Anyone designing and implementing a multicenter MUE is
likely to encounter several challenges, including coordinating
a single protocol among several investigators, obtaining ap-
proval frommultiple IRBs or ethics committees, ensuring uni-
versal data collection and quality control procedures, and se-
curing funding for staff time at each site. However, multicen-
ter MUEs would offer unique opportunities to decide which
data to collect and to include endpoints, such as pain scores,
functional outcomes, or patient satisfaction, that may not be
captured in any single database.
Conclusions
MUEs can be a valuable tool in the effort to improve patient
outcomes in postsurgical pain management. Typically designed
and conducted by an interdisciplinary team (e.g., pharmacists,
prescribers, nurses, administrators) operating with the consent
and support of the organization’s leadership, the most effective
MUEs have specific objectives and a scientifically robust study
design and data analysis plan. Results should be interpreted
with a focus on clinical relevance and improved patient out-
comes, and any recommended changes in prescribing behavior
or standard of care that result should be clearly communicated
to all stakeholders. A system to monitor compliance and incor-
porate feedback on the MUE process is also recommended.
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